BMJ  2007;335:319 (18 August), doi:10.1136/bmj.39307.630347.DB

News

High Court upholds NICE decision to limit treatments for Alzheimer's disease

London

The first 150 words of the full text of this article appear below.

Campaigners and drug makers failed last week in their High Court bid to overturn guidance recommending only limited coverage on the NHS of drugs to treat Alzheimer's disease. This was the first major legal challenge to guidance issued by the National Institute for Health and Clinical Excellence (NICE), the body that recommends which drugs are available on the NHS in England and Wales.

Mrs Justice Dobbs ordered NICE to amend the existing guidance, having ruled that its diagnostic criteria breached the Disability Discrimination Act and the Race Relations Act. NICE undertook to make the relevant changes within 28 days—but the core of the guidance will remain unchanged.

The guidance recommends against the use of donepezil (Aricept), rivastigmine (Exelon), and galantamine (Reminyl) in patients with mild to moderate Alzheimer's disease and against the use of memantine (Ebixa) in moderately severe to severe disease.

The court's decision means that the NHS will . . . [Full text of this article]

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

Related Articles

Appeal Court rules that NICE procedure was unfair

Clare Dyer
BMJ 2008 336: 1035. [Extract] [Full Text] [PDF]

News
BMJ 2007 335: 690. [Extract] [Full Text] [PDF]

The Alzheimer's Society, drug manufacturers, and public trust

Iain Chalmers
BMJ 2007 335: 400. [Extract] [Full Text] [PDF]

Why this unholy trinity?

Tony Delamothe
BMJ 2007 335: 0. [Extract] [Full Text]